Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations Meeting Abstract
| Authors: | Chi, K. N.; Rathkopf, D. E.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Gomes, A. J.; Roubaud, G.; Saad, M.; Zurawski, B.; Sakalo, V.; Mason, G.; del Corral, A.; Wang, G. C.; Wu, D.; Diorio, B.; Lopez-Gitlitz, A. M.; Sandhu, S. K. |
| Abstract Title: | Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900013 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.012 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 12 -- Meeting was conducted online as well as in person -- Source: Wos |
